natgillin/translations-raw huggingface dataset:
These generally occur within the first several months of therapy.
One su se općenito javljale unutar prvih nekoliko mjeseci terapije.
Caution is therefore recommended.
Stoga se preporučuje oprez.
- if you have ever had or might now have a hepatitis B infection.
- ako ste ikada imali ili možda sada imate infekciju virusom hepatitisa B.
Tell your doctor if you are using medicines that prevent the formation of blood clots.
Obavijestite svog liječnika ako koristite lijekove koji sprječavaju stvaranje krvnih ugrušaka.
Pliva Hrvatska d.o.o.
Hrvatska Pliva Hrvatska d.o.o.
Currently available published data are summarised in section 5.1 but no recommendation on a posology can be made.
Trenutačno dostupni objavljeni podaci sažeti su u dijelu 5.1, ali ne mogu se dati nikakve preporuke o doziranju.
However, always take this medicine exactly as your doctor or pharmacist has told you.
Međutim, uvijek uzmite ovaj lijek točno onako kako su Vam rekli Vaš liječnik ili ljekarnik.
The amount of Imatinib Actavis given will depend on your child's condition, body weight and height.
Količina Imatinib Actavisa koju je potrebno dati ovisiti će o stanju djeteta, tjelesnoj težini i visini.
If you think you may be allergic but are not sure, ask your doctor for advice.
Ako mislite da biste mogli biti alergični, ali niste sigurni, posavjetujte se sa svojim liječnikom.
The rate of haematological response was 70% with a duration of 2-3 months.
Stopa hematološkog odgovora bila je 70% uz trajanje od 2 do 3 mjeseca.
Your doctor has prescribed Imatinib Actavis because you suffer from a serious condition.
Vaš liječnik je propisao Imatinib Actavis jer patite od ozbiljnog stanja.
Mean absolute bioavailability for imatinib is 98%.
Srednja apsolutna bioraspoloživost za imatinib je 98%.
A major response combines both complete and partial responses: complete (0% Ph+ metaphases), partial (1-35%)
Veliki odgovor je kombinacija kompletnih i parcijalnih odgovora: kompletni (0% Ph+ metafaza), parcijalni (1-35%)
- if you are taking the medicine levothyroxine because your thyroid has been removed.
- ako uzimate lijek levotiroksin, jer Vam je uklonjena štitnjača.
Elderly patients: Imatinib pharmacokinetics have not been specifically studied in older people.
Stariji bolesnici: Farmakokinetika imatiniba nije specifično ispitivana u starijih ljudi.
In the rest of this leaflet, we will use the abbreviations when talking about these diseases.
U ostatku ove upute o lijeku koristiti ćemo kratice prilikom spominjanja ovih bolesti.
All treatment regimens include administration of steroids for CNS prophylaxis.
Svi režimi liječenja uključuju primjenu steroida radi CNS profilakse.
If you have any questions about how Imatinib Actavis works or why this medicine has been prescribed for you, ask your doctor.
Ako imate bilo kakvih pitanja o tome na koji način djeluje Imatinib Actavis, ili zašto je taj lijek Vama propisan, obratite se svom liječniku.
Therefore, the use of imatinib in combination requires special precaution.
Stoga primjena imatiniba u kombinaciji zahtijeva posebne mjere opreza.
No evidence of leukaemia (NEL)
Nema dokaza leukemije (NEL)
Some children and adolescents taking Imatinib Actavis may have slower than normal growth.
Kod neke djece i adolescenata koji uzimaju Imatinib Actavis rast može biti sporiji od normalnog.
2 Cytogenetic response criteria:
2 Kriteriji citogenetskog odgovora:
The median duration of therapy in the published literature ranged between 4 weeks and more than 20 months.
Medijan trajanja liječenja u objavljenoj literaturi kretao se između 4 tjedana i više od 20 mjeseci.
Complete (Confirmed3) [95% CI] Partial
(Potvrđeni3) [95% CI]
Out of the 12 patients enrolled, 9 responded, one completely and 8 partially.
Od 12 uključenih bolesnika, 9 je imalo odgovor, jedan potpuni, a 8 djelomični.
The median duration of therapy in study B2225 was 6.2 months, with a maximum duration of 24.3 months.
Medijan trajanja terapije u studiji B2225 iznosio je 6,2 mjeseca, s maksimalnim trajanjem od 24,3
Two intermediates of the manufacturing process, which are also present in the final product, are positive for mutagenesis in the Ames assay.
Dva međuproizvoda proizvodnog procesa, koji su također prisutni u gotovom proizvodu, su u Amesovom testu pozitivna na mutagenezu.
When needed, discontinuation of imatinib treatment may be considered.
Ukoliko je potrebno, može se razmotriti prekid liječenja imatinibom.
Considering the combined concentration of imatinib and the metabolite and the maximum daily milk intake by infants, the total exposure would be expected to be low (~10% of a therapeutic dose).
Uzimajući u obzir kombiniranu koncentraciju imatiniba i metabolita i maksimalni dnevni unos mlijeka od strane dojenčeta, očekuje se da je ukupna izloženost niska (~10% terapijske doze).
One blister contains 10 tablets.
Jedan blister sadrži 10 tableta.
It is important that you do this as long as your doctor or pharmacist tells you to.
Važno je da to činite onoliko dugo koliko Vam kaže liječnik ili ljekarnik.
The capsule contains light yellow powder.
Kapsula sadrži svijetložuti prašak.
The translocation t(17:22)[(q22:q13)], or its gene product, was present in nearly all responders to imatinib treatment.
Translokacija t(17:22)[(q22:q13)], ili njezin genski proizvod, je bila prisutna kod gotovo svih bolesnika koji su odgovorili na liječenje imatinibom.
Treatment was discontinued permanently because of liver laboratory abnormalities in less than 1% of CML patients.
Liječenje je trajno ukinuto zbog abnormalnih laboratorijskih vrijednosti jetre u manje od 1% bolesnika s KML-om.
- If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Ako ste trudni ili dojite, mislite da biste mogli biti trudni ili planirate imati dijete, obratite se svom liječniku za savjet prije nego uzmete ovaj lijek.
Pericarditis*, cardiac tamponade*
Perikarditis*, tamponada srca*
- If you are being treated for Ph-positive ALL:
Ako se liječite zbog Ph-pozitivnog ALL-a:
The complete molecular response rate was 48% (49 out of 102 evaluable patients).
Potpuni molekularni odgovor postignut je u 48% (49 od 102 procijenjena bolesnika).
It is important to cover sunexposed areas of skin and use sunscreen with high sun protection factor (SPF).
Važno je pokriti područja kože izložena suncu i koristiti sredstvo za zaštitu od sunca s visokim zaštitnim faktorom (SPF).
2 Headache was the most common in GIST patients.
2 Glavobolja je bila najčešća u GIST bolesnika.
Considering the limited safety database, the adverse events thus far reported in children are consistent with the known safety profile in adult patients with Ph+ ALL.
Imajući na umu ograničenost baze podataka o sigurnosti primjene, dosad prijavljeni štetni događaji u djece odgovaraju poznatome sigurnosnom profilu u odraslih bolesnika s Ph+ ALL.
Imatinib Actavis can help you to fight this condition.
Imatinib Actavis Vam može pomoći u borbi protiv tog stanja.
Imatinib Actavis may do the same to some other medicines.
Imatinib Actavis može to isto napraviti nekim drugim lijekovima.
Hypersensitivity to soya or peanut.
Preosjetljivost na soju ili kikiriki.
Exposure to direct sunlight should be avoided or minimised due to the risk of phototoxicity associated with imatinib treatment.
Izlaganje izravnoj sunčevoj svjetlosti je potrebno izbjegavati ili minimizirati zbog rizika od fototoksičnosti povezanog s liječenjem imatinibom.
If you take more Imatinib Actavis than you should
Ako uzmete više Imatinib Actavisa nego što ste trebali
Use only as directed by a doctor.
Primjenjivati isključivo prema uputama liječnika.
The rate of response was also higher in the patients treated at 600 mg (33%) as compared to the patients treated at 400 mg (16%, p=0.0220).
Stopa odgovora također je bila viša u bolesnika koji su liječeni s dozom od 600 mg (33%) u usporedbi s bolesnicima koji su liječeni s 400 mg (16%, p=0,0220).
very rare (<1/10,000), not known (cannot be estimated from the available data).
(<1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription (such as paracetamol) and including herbal medicines (such as St. John's Wort).
Obavijestite svog liječnika ili ljekarnika ako uzimate ili ste nedavno uzeli ili biste mogli uzeti bilo koje druge lijekove, uključujući lijekove dobivene bez recepta (poput paracetamola) i biljne pripravke
Imatinib administration to patients without the genetic translocation generally results in no improvement.
Primjena imatiniba bez genetske translokacije obično ne rezultira poboljšanjem.
- Once the tablet has dissolved, drink everything in the glass straight away.
- Jednom kad se tableta otopi, odmah popijte sav sadržaj čaše.
- Dermatofibrosarcoma protuberans (DFSP).
- Dermatofibrosarkoma protuberans (DFSP).
- Pain in your hips or difficulty walking.
- bol u kukovima ili otežano hodanje.
Patients should be instructed to use measures such as protective clothing and sunscreen with high sun protection factor (SPF).
Bolesnike je potrebno uputiti na korištenje mjera kao što su zaštitna odjeća i sredstvo za sunčanje s visokim faktorom zaštite od sunca (SPF).
- Women who might become pregnant are advised to use effective contraception during treatment.
- Ženama koje mogu zatrudnjeti se savjetuje primjena učinkovite kontracepcije tijekom liječenja.
Contains lecithin (soya) (E322).
Sadrži sojin lecitin (E322).
- Slowing of growth in children and adolescents.
- usporen rast djece i adolescenata.
- Swallow the capsules whole with a large glass of water.
- Kapsule progutajte cijele s velikom čašom vode.
Imatinib Actavis can reduce the number of white blood cells, so you might get infections more easily.
Imatinib Actavis može smanjiti broj bijelih krvnih stanica, pa možete lakše dobiti infekciju.
- Weight gain.
- dobivanje na težini.
While you are taking Imatinib Actavis, your doctor will regularly check whether the medicine is working.
Dok uzimate Imatinib Actavis, liječnik će redovito pratiti da li lijek djeluje.
In a recent publication updated information from 6 of these 11 patients revealed that all these patients remained in cytogenetic remission (range 32-38 months).
U nedavnoj publikaciji, novije informacije o 6 od tih 11 bolesnika otkrile su da su svi ti bolesnici ostali u citogenetskoj remisiji (raspon 32-38 mjeseci).
Do not stop taking Imatinib Actavis unless your doctor tells you to.
Nemojte prestati uzimati Imatinib Actavis, osim ako Vam to ne kaže liječnik.
The estimated 4-year OS in cohort 5-patients was 83.6% compared to 44.8% in the historical controls.
Procijenjeno 4-godišnje ukupno preživljavanje u bolesnika u kohorti 5 bilo je 83,6% u usporedbi s 44,8% u kontrolnoj kohorti.
- Stir with a spoon until the tablets have completely dissolved.
- Miješajte žlicom sve dok se tableta potpuno ne otopi.
The first 37 patients were started at 400 mg, the protocol was subsequently amended to allow higher dosing and the remaining 223 patients were started at 600 mg.
37 bolesnika liječenje je započelo s dozom od 400 mg, protokol je naknadno promijenjen tako da je dozvoljavao veće doziranje, pa je ostalih 223 bolesnika započelo s dozom od 600 mg.
Plasma pharmacokinetic profiles were analysed on day 1 and on either day 7 or day 28, by which time plasma concentrations had reached steady state.
Farmakokinetički profili u plazmi analizirani su na dan 1 te ili na dan 7 ili na dan 28, a do toga su vremena koncentracije u plazmi postigle stanje dinamičke ravnoteže.
Confusional state
Konfuzno stanje
The prescribed dose should be administered orally with a meal and a large glass of water to minimise the risk of gastrointestinal irritations.
Preporučenu dozu treba primjenjivati peroralno, uz obrok i veliku čašu vode, da bi se rizik od gastrointestinalnih iritacija sveo na najmanju moguću mjeru.
- Unexpected bleeding or bruising (when you have not hurt yourself).
- neočekivano krvarenje ili pojava modrica (kada se niste ozlijedili).
Blast crisis is defined as blasts ≥ 30% in blood or bone marrow or extramedullary disease other than hepatosplenomegaly.
Blastična se kriza definira kao blasti ≥30% u krvi ili koštanoj srži ili postojanje ekstramedularne bolesti osim hepatosplenomegalije.
The duration of imatinib therapy can vary with the treatment programme selected, but generally longer exposures to imatinib have yielded better results.
Trajanje terapije imatinibom može se razlikovati s obzirom na odabrani program liječenja, no općenito se može reći da su se dužom izloženošću imatinibu dobivali bolji rezultati.
The high rate of CHR is accompanied by the development of a complete cytogenetic response (CCyR) of 65% which is comparable to the results observed in adults.
Visoka stopa CHR-a je praćena razvojem potpunog citogenetskog odgovora (CCyR) od 65% što je usporedivo s rezultatima dobivenim u odraslih.
All patients received imatinib and consolidation chemotherapy (see Table 3) after induction and the levels of bcr-abl transcripts were identical in the two arms at 8 weeks.
Svi su bolesnici primili imatinib i konsolidacijsku kemoterapiju (vidjeti Tablicu 3) nakon indukcije, a razine bcr-abl transkripcije bile su identične u dva kraka nakon 8 tjedana.
8 to 10 g (single dose): Vomiting and gastrointestinal pain have been reported.
8 do 10 g (jednokratna doza): zabilježeni su povraćanje i bolovi u trbuhu.
Imatinib and the N-demethyl metabolite together accounted for about 65% of the circulating radioactivity (AUC(0-48h)).
Imatinib i N-demetil metabolit zajedno su bili odgovorni za oko 65% cirkulirajuće radioaktivnosti (AUC(0-48h)).
This may be a sign of damage to blood vessels known as thrombotic microangiopathy (TMA).
To može biti znak oštećenja krvnih žila znan kao trombotična mikroangiopatija (TMA).
These changes are not considered sufficient to warrant dose adjustment based on kg bodyweight.
Za ove se promjene smatra da nisu dovoljne da bi opravdale prilagođavanje doze prema kilogramima tjelesne težine.
In children and adolescents, Imatinib Actavis can be used in different phases of the disease (chronic, accelerated phase and blast crisis).
U djece i adolescenata Imatinib Actavis se može koristiti u različitim fazama bolesti (kroničnoj fazi, ubrzanoj fazi i blastičnoj krizi).
Study AJP01
Studija AJP01
- Imatinib Actavis is not recommended during pregnancy unless clearly necessary as it may harm your baby.
- Imatinib Actavis se ne smije upotrebljavati tijekom trudnoće, osim ako to nije neophodno, jer može naškoditi Vašem djetetu.
During treatment with Imatinib Actavis, tell your doctor straight away if you put on weight very quickly.
Tijekom liječenja Imatinib Actavisom odmah obavijestite svog liječnika ako vrlo brzo dobivate na težini.
However, the marketing authorisation holder shall submit periodic safety update reports for this medicinal product if the product is included in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.
Nositelj odobrenja će periodička izvješća o neškodljivosti podnositi ako je lijek uvršten u referentni popis datuma EU (EURD popis) predviđenim člankom 107(c) stavkom 7 Direktive
In clinical trials, there was an increased incidence of these events in elderly patients and those with a prior history of cardiac disease.
U kliničkim je ispitivanjima zabilježena povećana incidencija tih događaja u starijih bolesnika te u onih koji su ranije bolovali od bolesti srca.
The score line is not intended for breaking the tablet.
Razdjelna linija nije namijenjena za lomljenje tablete.
Ki values in human liver microsomes were 27, 7.5 and 7.9 μmol/L, respectively.
Ki vrijednosti u jetrenim mikrosomima čovjeka bile su 27, 7,5, odnosno 7,9 μmol/l.
If anti-ADAMTS13-antibody is elevated in conjunction with low ADAMTS13 activity, treatment with Imatinib Actavis should not be resumed.
Ako su anti-ADAMTS13-protutijela povišena istodobno sa sniženom ADAMTS13 aktivnosti, liječenje Imatinibom Actavis ne smije se nastaviti.
Study ADE04
Studija ADE04
Some medicines can interfere with the effect of Imatinib Actavis when taken together.
Neki lijekovi mogu utjecati na djelovanje Imatinib Actavisa kada se uzimaju zajedno.
Dose increase from 100 mg to 400 mg may be considered in the absence of adverse drug reactions if assessments demonstrate an insufficient response to therapy.
Povećanje doze od 100 mg do 400 mg može se razmotriti u odsustvu nuspojava, ako se pregledom utvrdi nedovoljan odgovor na terapiju.
21 patients were treated with imatinib 400 mg daily, while the other 3 patients received lower doses.
21 bolesnik je liječen imatinibom 400 mg na dan, dok su preostala 3 bolesnika primala niže doze.
In the clinical study 38% of patients were ≥ 60 years of age and 12% of patients were ≥ 70 years of age.
U kliničkom ispitivanju 38% bolesnika bilo je u dobi ≥60 godina, a 12% bolesnika bilo je u dobi
The age of the DFSP patients ranged from 23 to 75 years; DFSP was metastatic, locally recurrent following initial resective surgery and not considered amenable to further resective surgery at the time of study entry.
Dob bolesnika s DFSP-om kretala se od 23 do 75 godina; DFSP je bio metastazirajući, lokalno recidivirajući nakon inicijalnog resekcijskog kirurškog zahvata te nije smatran podobnim za dodatni resekcijski kirurški zahvat u trenutku uključivanja u studiju.
Experience with imatinib in this indication is very limited and is based on haematological and cytogenetic response rates.
Iskustvo s imatinibom u ovoj indikaciji je vrlo ograničeno te se temelji na hematološkom i citogenetskom odgovoru.
Contents of the pack and other information What Imatinib Actavis contains
Sadržaj pakiranja i druge informacije Što Imatinib Actavis sadrži
Thrombosis/embolism*
Tromboza/embolija*
The dose recommendation is currently based on a small number of paediatric patients (see sections 5.1 and 5.2).
Postojeća preporuka doziranja temeljena je na malenom broju pedijatrijskih bolesnika (vidjeti dijelove 5.1 i 5.2).
The effect of prior gastrointestinal surgery on drug absorption has not been investigated.
Učinak prethodnog gastrointestinalnog kirurškog zahvata na apsorpciju lijeka nije ispitan.
Hands should be washed immediately after handling open capsules.
Ruke se trebaju oprati odmah nakon rukovanja otvorenim kapsulama.
Based on population pharmacokinetic analysis in CML patients, there was a small effect of age on the volume of distribution (12% increase in patients > 65 years old).
Na temelju analize farmakokinetike populacije u KML bolesnika, učinak dobi na volumen raspodjele bio je malen (povećanje od 12% u bolesnika starih >65 godina).
The experience with imatinib in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1).
Iskustvo s imatinibom u bolesnika s MDS/MPD-om povezanim s preraspodjelom gena za PDGFR je vrlo ograničeno (vidjeti dio 5.1).
You may become more sensitive to the sun while taking Imatinib Actavis.
Možete postati osjetljiviji na sunce tijekom uzimanja Imatiniba Actavis.
- Unusual hair loss or thinning.
- neuobičajen gubitak ili prorijeđenost kose.
Table 1 Tabulated summary of adverse reactions Infections and infestations
Tablica 1 Tablični sažetak nuspojava Infekcije i infestacije
Your doctor will discuss with you the possible risks of taking Imatinib Actavis during pregnancy.
Liječnik će Vam objasniti moguće rizike od uzimanja Imatinib Actavisa tijekom trudnoće.
* These types of reactions have been reported mainly from post-marketing experience with imatinib.
* Ove vrste reakcija zabilježene su uglavnom nakon stavljanja imatiniba u promet.
- Eye pain or deterioration in vision, bleeding in the eyes.
- bol u očima ili slabljenje vida, krvarenje u očima.
5 patients responded, 3 completely and 2 partially.
Pet (5) bolesnika je imalo odgovor, 3 potpuni i 2 djelomični.
- if you are allergic to imatinib or any of the other ingredients of this medicine (listed in section 6).
- ako ste alergični na imatinib ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
- Recurrence (reactivation) of hepatitis B infection when you have had hepatitis B in the past (a liver infection).
- ponovna pojava (ponovna aktivacija) infekcije virusom hepatitisa B ako ste u prošlosti imali hepatitis B (infekciju jetre).
Study AUS01
Studija AUS01
They may increase or decrease the effect of Imatinib Actavis, either leading to increased side effects or making Imatinib Actavis less effective.
Oni mogu povećati ili smanjiti učinak Imatinib Actavisa bilo povećanjem nuspojava ili smanjenjem učinka Imatinib Actavisa.
There have been post-marketing reports of spontaneous abortions and infant congenital anomalies from women who have taken imatinib.
Postoje post-marketinška izvješća o spontanim pobačajima i dojenčadi s kongenitalnim anomalijama u žena koje su uzimale imatinib.
- Swallow the tablets whole with a large glass of water.
- Tablete progutajte cijele s velikom čašom vode.
Pancytopenia, febrile neutropenia
Pancitopenija, febrilna neutropenija
Disease-free survival (DFS) and overall survival (OS) constantly exceeded 1 year and were superior to historical control (DFS p<0.001; OS p<0.0001) in two studies (AJP01 and AUS01).
Preživljenje bez bolesti (DFS) i ukupno preživljenje (OS) stalno premašuju 1 godinu te su superiorni nad prethodnim kontrolama (DFS p<0,001; OS p<0,0001) u dva ispitivanja (AJP01 i AUS01).
This will help protect you from stomach problems when taking Imatinib Actavis.
To će Vam pomoći u zaštiti od želučanih problema prilikom uzimanja Imatinib Actavisa.
- Numbness of the hands or feet.
- utrnulost šaka ili stopala.
In adult patients, Imatinib Actavis is intended for use in the most advanced phase of the disease (blast crisis).
U odraslih bolesnika Imatinib Actavis namijenjen je za primjenu u fazi najvećeg uznapredovanja bolesti (blastičnoj krizi).
Due to the observational nature of this registry, haematologic, cytogenetic and molecular assessment data were available for 22, 9 and 17 of the 23 enrolled patients, respectively.
Zbog opservacijske prirode ovog registra, podaci hematološke, citogenetske i molekularne procjene bili su dostupni za 22, 9 odnosno 17
Imatinib Actavis may cause your body to retain water (severe fluid retention).
Imatinib Actavis može izazvati zadržavanje vode u tijelu (teška retencija tekućine).
Severe elevation of transaminases (<5%) or bilirubin (<1%) was seen in CML patients and was usually managed with dose reduction or interruption (the median duration of these episodes was approximately one week).
Veliko povišenje vrijednosti transaminaza (<5%) ili bilirubina (<1%) uočeno je u bolesnika s KMLom i obično je liječeno smanjenjem doze ili prekidom terapije (medijan trajanja tih epizoda bio je približno tjedan dana).
If you have accidentally taken too many capsules, talk to your doctor straight away.
Ako ste zabunom uzeli previše kapsula, odmah se obratite liječniku.
Alternating chemotherapy course: high dose chemotherapy with MTX 1 g/m2 i.v.
Izmjenični tijek kemoterapije: visoka doza kemoterapije s MTX 1 g/m2 i.v.
Patients should be tested for HBV infection before initiating treatment with Imatinib Actavis.
Bolesnike je potrebno testirati na infekciju HBV-om prije početka liječenja Imatinibom Actavis.
Haematological and cytogenetic responses have been sustained for a median of 49 months (range 19-60) and 47 months (range 16-59),
Hematološki i citogenetski odgovori su se održali za medijan od 49 mjeseci (raspon 19-60), odnosno 47 mjeseci (raspon 16-59).
3 Complete cytogenetic response confirmed by a second bone marrow cytogenetic evaluation performed at least one month after the initial bone marrow study.
3 Potpuni citogenetski odgovor potvrđen drugom citogenetskom procjenom koštane srži koja je provedena najmanje jedan mjesec nakon početnog ispitivanja koštane srži.
In this study, 31% of patients achieved a haematological response (36% in previously untreated patients and 22% in previously treated patients) (Table 2).
U tom je ispitivanju 31% bolesnika postiglo hematološki odgovor (36% u skupini prethodno neliječenih bolesnika i 22% u skupini prethodno liječenih bolesnika) (Tablica 2).